Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.39 |
| ▸ | DRD3 | P35462 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482922 | 0.88 | SMYD2 (0.38) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL2993811 | 0.87 | PER2 (0.40) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL3757378 | 0.85 | SMYD2 (0.37) | PER2SMYD2TAS2R8CYP3A4HTT | |
| SCHEMBL3745187 | 0.84 | MAPT (0.37) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL3760372 | 0.83 | SMYD2 (0.36) | PER2SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21595114 | 0.81 | PER2 (0.37) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL21594911 | 0.81 | PER2 (0.39) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL2994194 | 0.79 | PER2 (0.36) | PER2DRD2DRD3KCNH2SMYD2 | |
| SCHEMBL28572852 | 0.76 | CYP2D6 (0.39) | PER2DRD2DRD3KCNH2HDAC1 | |
| SCHEMBL21594937 | 0.76 | SMYD2 (0.35) | PER2DRD2DRD3KCNH2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626969-A1 | HETEROCYCLIC COMPOUNDS | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | PER2 2557/4885DRD2 1762/4885DRD3 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.